Analysts expect that Xencor Inc (NASDAQ:XNCR) will report sales of $6.73 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Xencor’s earnings. The highest sales estimate is $10.30 million and the lowest is $4.07 million. Xencor posted sales of $11.56 million during the same quarter last year, which indicates a negative year over year growth rate of 41.8%. The company is scheduled to announce its next earnings results on Monday, February 24th.
On average, analysts expect that Xencor will report full year sales of $159.92 million for the current year, with estimates ranging from $157.26 million to $163.50 million. For the next year, analysts expect that the firm will post sales of $63.45 million, with estimates ranging from $24.89 million to $112.16 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Xencor.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.40. Xencor had a net margin of 21.60% and a return on equity of 5.84%. The company had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million.
XNCR has been the topic of a number of recent research reports. BidaskClub raised shares of Xencor from a “sell” rating to a “hold” rating in a research report on Thursday. Mizuho reaffirmed a “buy” rating on shares of Xencor in a research report on Tuesday, November 5th. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. ValuEngine raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Raymond James reaffirmed a “market perform” rating on shares of Xencor in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $43.90.
A number of hedge funds have recently added to or reduced their stakes in the business. First Trust Advisors LP boosted its stake in shares of Xencor by 185.4% in the 1st quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company’s stock valued at $2,167,000 after purchasing an additional 45,331 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of Xencor in the 2nd quarter valued at approximately $794,000. Oregon Public Employees Retirement Fund acquired a new stake in Xencor during the 2nd quarter worth approximately $409,000. Quantitative Systematic Strategies LLC acquired a new stake in Xencor during the 2nd quarter worth approximately $344,000. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in Xencor by 64.6% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 26,809 shares of the biopharmaceutical company’s stock worth $1,097,000 after buying an additional 10,520 shares during the period. 92.63% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:XNCR traded up $0.37 during mid-day trading on Wednesday, reaching $38.36. 18,113 shares of the company’s stock were exchanged, compared to its average volume of 271,065. Xencor has a one year low of $27.75 and a one year high of $46.33. The firm has a market capitalization of $2.18 billion, a PE ratio of -29.23 and a beta of 1.34. The business’s fifty day simple moving average is $35.30 and its two-hundred day simple moving average is $36.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.92 and a current ratio of 8.92.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: Retained Earnings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xencor and related companies with MarketBeat.com’s FREE daily email newsletter.